Iradimed CORP 8-K Filing
Ticker: IRMD · Form: 8-K · Filed: Dec 8, 2025 · CIK: 1325618
Sentiment: neutral
Filing Stats: 526 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2025-12-08 08:30:20
Key Financial Figures
- $0.0001 — h registered: Common stock, par value $0.0001 IRMD NASDAQ Capital Market Item 8
- $0.50 — e Company's outstanding common stock of $0.50 per share. The special dividend is paya
Filing Documents
- irmd-20251205x8k.htm (8-K) — 37KB
- irmd-20251205xex99d1.htm (EX-99.1) — 13KB
- irmd-20251205xex99d1001.jpg (GRAPHIC) — 17KB
- 0001104659-25-119090.txt ( ) — 184KB
- irmd-20251205.xsd (EX-101.SCH) — 3KB
- irmd-20251205_lab.xml (EX-101.LAB) — 15KB
- irmd-20251205_pre.xml (EX-101.PRE) — 10KB
- irmd-20251205x8k_htm.xml (XML) — 5KB
01. Other Events
Item 8.01. Other Events. On December 5, 2025, the Board of Directors of IRADIMED CORPORATION declared a special cash dividend on the Company's outstanding common stock of $0.50 per share. The special dividend is payable on December 30, 2025, to shareholders of record at the close of business on December 17, 2025. The information in this Item 8.01, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that Section. Furthermore, such information, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. A copy of the press release is attached as Exhibit 99.1 to this report.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated Decmber 8, 2025, announcing Special Cash Dividend of $0.50 per share 104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IRADIMED CORPORATION Date: December 8, 2025 By: /s/ John Glenn Name: John Glenn Title: Chief Financial Officer